---
title: "Hepatitis C treatment access in Los Angeles County: barriers, facilitators, and linkage-to-cure fi"
id: "plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363327"
published_at: "2026-11-20T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Hepatitis C treatment access in Los Angeles County: barriers, facilitators, and linkage-to-cure fi
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363327)
- **Published At:** 2026-11-20T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Project HCV Connect program data from 344 LA County case-residents (Oct 2024–Jan 2025) formed the quantitative base; 49% were already treated and 51% untreated at contact. - Overall, 54% of case-residents reported at least one barrier to care; the study team used frequencies and percentages for descriptive analysis. - Among those reporting specific barriers (n = 91), investigators classified the problems: personal barriers were most frequent (43%), provider-related barriers second (31%), followed by insurance barriers (13%) and inadequate access to medical care (13%). - The qualitative strand comprised 10 semi-structured interviews (7 untreated, 3 treated) conducted in English and Spanish to contextualize program data and to explore HBM and TTM-informed constructs. - Untreated participants identified twelve parent themes; prominent barriers in interviews included homelessness, incarceration, active substance use, high treatment cost concerns, language barriers, transportation challenges, lack of information, and difficulty navigating the healthcare system. - Provider-related barriers noted by participants included poor follow-up, long wait times, limited HCV information provision, and perceived dismissive care; Spanish-speaking participants described pronounced language-communication problems. - Facilitators reported were personal motivation, family and community support, trust in a provider, adequate insurance coverage, understanding benefits of HCV treatment, and desire to avoid stigma. - Suggested program strategies aligned with participant reports: language support services, patient navigation and care coordination, mobile clinics for unhoused populations, continuity of care after incarceration, and removal of insurance restrictions such as prior authorization. - Quantitative data analysis omitted inferential testing because many barrier subcategories had n < 15; qualitative coding used inductive thematic analysis without member-checking. - Data and interview excerpts are available via Figshare DOI provided in the source; the study received USC IRB approval and reported no competing interests.
## Clinical Analysis & Structured Key Points
Exploring barriers and facilitators to Hepatitis C virus treatment access in Los Angeles County: A mixed-methods study | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Peer Review Reader Comments Figures Figures Abstract Diagnosed but untreated chronic Hepatitis C virus infection remains an important public health problem in Los Angeles County, particularly affecting underserved and minority groups. This mixed-methods study (October 2024-January 2025) aimed to identify and describe the barriers and facilitators to accessing Hepatitis C virus treatment among Los Angeles County residents. The study used de-identified programmatic data from 344 case-residents in a linkage-to-cure program and conducted thematic analysis of semi-structured interviews with ten participants (seven untreated, three treated) from the linkage-to-cure program. Overall, 54% of case-residents reported experiencing barriers. Among those reporting specific barriers (n = 91), personal barriers were most common (43%), followed by provider-related barriers (31%), insurance barriers (13%), and inadequate access to medical care (13%). Interviews provided further context. Themes identified included homelessness, incarceration, and drug addiction as key personal barriers. Provider-related barriers included language barriers, expressed frustration in navigating the healthcare system, long wait times to see a provider, and participants’ lack of HCV information. Insurance barriers were characterized by cost barriers and inadequate access to medical care due to a lack of transportation. Facilitators of treatment access included personal motivation to seek treatment, family and community-based support systems, trust in their medical provider, adequate insurance coverage, understanding the benefits of HCV treatment, and the desire to avoid stigmatization. Local efforts to eliminate Hepatitis C should consider equitable interventions that address individual and system-level barriers. Potential strategies include implementing language support services, leveraging patient navigation and care coordination services, utilizing mobile clinics for the unhoused, ensuring treatment continuity for people re-entering the community from incarceration, and removing insurance restrictions, such as prior authorization requirements. Citation: Handa S, Sudeep N, Albers L, Pattarroyo M, Vasquez J, Montgomerie RE, et al. (2026) Exploring barriers and facilitators to Hepatitis C virus treatment access in Los Angeles County: A mixed-methods study. PLoS One 21(11): e0363327. https://doi.org/10.1371/journal.pone.0363327 Editor: Yury E. Khudyakov, Centers for Disease Control and Prevention, UNITED STATES OF AMERICA Received: April 28, 2026; Accepted: November 7, 2026; Published: November 20, 2026 Copyright: © 2026 Handa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The quantitative data and qualitative interview excerpts are available in the Figshare repository via DOI: 10.6084/m9.figshare.31476604 . Funding: Project activities were partially supported by USC and the Southern California Clinical and Translational Science Institute ( https://sc-ctsi.org/nih-funding-acknowledgement ), Grant #UL1TR001855 (received by JDK, DS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Background Chronic Hepatitis C virus (HCV) infection is an asymptomatic infectious disease that affects the liver. Globally, Hepatitis C is a major cause of liver transplants [ 1 ]. Hepatitis C is primarily a result of blood-to-blood transmission, spread by needles shared during intravenous drug usage [ 2 ]. Without treatment, HCV-infected individuals can develop liver failure, liver cancer, cirrhosis, and die prematurely [ 1 ]. HCV infection can be cured with eight to 12 weeks of daily oral treatment with the use of direct-acting antiviral medication. Hepatitis C virus in Los Angeles County More than five million Americans, or around two percent of the American adult population, have anti-HCV antibodies, suggesting prior or current infection [ 3 ]. In Los Angeles (LA) County, California, 27,678 people were diagnosed with HCV between 2019 and 2023, but only 30% of people reported knowledge of HCV treatment [ 4 ]. Treatment completion rates remain low, with only 32% of people completing HCV treatment [ 5 ]. Notably, non-White minority groups, particularly Hispanic, Latino, or Black, had the lowest percentages of reported treatment completion [ 5 ]. Recent policy changes in Medi-Cal, such as the removal of prior authorization and prescriber restrictions for HCV treatment [ 6 ], were intended to improve access. However, significant obstacles remain, including structural issues in the healthcare system, provider-related practices, and patient-level factors such as stigma [ 7 ]. In particular, gaps remain in understanding the unique experiences of Spanish-speaking Latinx individuals, who represent a significant proportion of the untreated population. Since healthcare experiences differ substantially between those who are untreated and treated, behavioral health frameworks are necessary to guide behavior change to receive HCV treatment. The Transtheoretical Model (TTM) helps researchers understand individual stages of change and therefore guided our decision to recruit and interview treated and untreated individuals. Additionally, findings were contextualized based on differences between treated participants, who likely reside in the action and maintenance phases, and untreated individuals, who are typically in the earlier phases of the TTM (e.g., precontemplation, contemplation, and planning). The Health Belief Model (HBM) has been used successfully in several studies of HCV infection [ 8 – 10 ]. Therefore, the interview guide for the present study was influenced by Health Belief Model (HBM) constructs such as perceived susceptibility, severity, threat, benefits, barriers, and self-efficacy [ 11 ]. The HBM provides a theory-driven way to examine the individual decision-making processes that may occur between HCV diagnosis and treatment initiation. We adapted the HBM to recognize that treatment initiation is influenced not only by individual beliefs but also by healthcare-system and structural factors identified as barriers to treatment adherence. Accordingly, HBM constructs were used to guide assessment of individual-level determinants of treatment-seeking, while additional domains examined insurance, healthcare access, provider-related barriers, and state and local policies. This approach allows us to distinguish potentially modifiable individual beliefs from structural barriers requiring health-system or policy interventions. Thus, the HBM provides both an explanatory framework for understanding the gap between HCV diagnosis and treatment and a theory-informed basis for identifying targets for future linkage-to-care interventions. Methods Study design and rationale This study utilized a mixed-methods approach to evaluate the barriers and facilitators to accessing HCV treatment among LA County residents from October 2024 to January 2025. Data were derived from Project HCV Connect, a linkage-to-cure program based in LA County. We used a convergent parallel mixed-methods design, in which quantitative and qualitative data were collected during the same period, analyzed separately, and then merged during interpretation [ 12 , 13 ]. The quantitative component was prioritized. We combined the two approaches because linkage-to-cure data could show how often treated and untreated HCV individuals reported barriers and which types they reported, but not why those barriers occurred or how they shaped treatment decisions. Interviews with treated and untreated participants provided this context and allowed us to check whether participants’ accounts aligned with the program data. Integration occurred at two points. First, at sampling. Interview participants were drawn from the same linkage-to-cure population as the quantitative data, and purposive sampling was based on treatment status, a variable recorded in the program data. Second, at interpretation. Quantitative barrier categories and qualitative themes were compared side by side in the Discussion to identify areas of convergence, expansion, and divergence. Specifically, we attempted to answer the following research questions: (RQ1) Quantitative: What proportion of LA County residents face barriers to accessing treatment for HCV, and what are the specific barriers they experience? (RQ2) Qualitative: How do the experiences of treated and untreated LA County residents explain the barriers identified in the quantitative program data, and what additional factors do they identify as hindering or facilitating their HCV treatment journeys? Participants and recruitment In collaboration with the LA County Department of Public Health (DPH), the University of Southern California (USC) established Project HCV Connect, a linkage-to-cure program [ 14 ]. This program uses the LA County DPH’s HCV surveillance registry, which aggregates data from all laboratory-confirmed HCV-RNA-positive test results of non-incarcerated LA County residents aged 18 or older. Data are cross-referenced to create a person-level HCV registry by relating all HCV-RNA test results to unique persons (defined as case-residents). Program personnel contact case-residents via telephone, provide HCV education and assess whether residents are aware of their diagnosis, evaluate specific barriers preventing treatment, determine if they have taken steps toward treatment, and gauge if they are interested in linkage-to-cure services. Interested residents are linked to HCV treatment with their primary care provider, community health clinics, or a telehealth program, coordinated directly by the program personnel based on healthcare network and insurance coverage. For the purposes of this study, we extracted and analyzed de-identified programmatic data to evaluate the barriers for case-residents during the analysis period. We invited a subset of those contacted to participate in a 30- to 60-minute semi-structured qualitative interview to explore the quantitative findings further. Participants met the inclusion criteria if (1) they had a confirmed HCV-RNA-positive result, (2) were LA County residents, and (3) were 18 years old or older. Interviews were conducted in English and Spanish. Data collection For the quantitative analysis, anonymous data were extracted from the linkage-to-cure program between October 2024 and January 2025. Data extracted included demographics (sex, age group, race/ethnicity), health insurance type, treatment status, willingness to receive treatment, and specific reported HCV barriers to treatment. The TTM and HBM help explain treatment-seeking behaviors [ 11 ]. To understand why individuals choose or delay treatment and identify potentially modifiable factors for future interventions, interview guides were influenced by TTM and HBM and tailored to treated and untreated HCV study participants. Questions about treatment journey and medication adherence were asked of treated study participants, but not of untreated study participants. This allowed for the development of a targeted guide that assessed knowledge, attitudes, and beliefs among treated and untreated HCV study participants. Interview guides explored study participant-level treatment barriers, including stigma, insurance challenges, and health literacy, as well as facilitators such as strategies to improve treatment linkage. Interviews were conducted on Zoom by graduate student volunteers and USC research staff trained in qualitative methods, cultural sensitivity, and bilingual (English/Spanish) interview techniques. All participants signed a consent form agreeing to the interview. Specific members of the research team (S.H., N.S., M.P., J.V., R.E.M., and R.M.N.) conducted the qualitative work. Interviews were audio-recorded, transcribed verbatim, and stored securely on the USC OneDrive. Data were deidentified by removing all identifying information, including names, ages, addresses, and interview dates, and assigning each participant a unique ID number to keep their information confidential. Participants could use pseudonyms to protect their privacy and received a $100 electronic gift card upon completion. Data analysis The quantitative analysis is presented with descriptive statistics, utilizing frequencies and percentages. Data were analyzed using SAS Software Version 9.4. Inferential statistical analyses were not performed because the majority of sample sizes in specific sub-categories of reported barriers were n < 15, which would not support robust analyses. For the qualitative part of the analysis, an inductive coding approach was employed to analyze interviews with untreated and treated study participants [ 15 , 16 ]. Thematic analysis was conducted through iterative coding of interview transcripts from study participant groups using Dedoose Version 9.2.22, a cloud-based qualitative analysis platform. To ensure analytical rigor, all transcripts were independently coded by members of the research team, including student volunteers and research staff. The research team then met regularly to compare codes and resolve coding discrepancies. Codes were developed collaboratively through repeated immersion in the data, with themes refined through comparative analysis across participant narratives. Although we did not conduct member-checking or participant transcript validation, our coders were content experts who have worked directly with HCV-positive individuals. To contextualize and interpret qualitative findings, HBM constructs such as self-efficacy, perceived benefits, and perceived barriers provided a framework for interpreting exploratory findings [ 11 ]. TTM informed how findings were organized. Because treatment status reflects different stages of behavior change, findings were analyzed separately for untreated and treated participants and compared across the two groups [ 11 ]. TTM constructs were not coded or analyzed directly. Ethical considerations The study received USC Institutional Review Board (IRB) approval (UP-24–00296). All interview participants provided verbal informed consent before participation. Results From October 2024 to January 2025, LA County DPH case managers contacted 344 people with a reported HCV-positive test result. Among them, 168 (49%) were already treated for Hepatitis C, and 176 had not received any treatment. Table 1 indicates that 54% of the study participants faced barriers to Hepatitis C treatment. The most reported barriers to treatment were personal barriers, namely that it was not a personal health priority to start treatment, followed by issues with the medical provider, such as incomplete follow-up after initial visit. Lack of insurance and inadequate access to medical care were also barriers to HCV treatment. Download: PNG larger image TIFF original image Table 1. Demographic characteristics of Hepatitis C linkage-to-cure contacts (n = 344) with HCV RNA-positive test result, Los Angeles County, October 2024 to January 2025. https://doi.org/10.1371/journal.pone.0363327.t001 We completed individual interviews with untreated study participants (n = 7) and treated study participants (n = 3). Of the untreated study participants, three were Spanish speakers, and four were English speakers. All three treated study participants were English speakers. Barriers to accessing Hepatitis C treatment among untreated English and Spanish-speaking study participants A total of twelve parent codes/themes were created for untreated study participant narratives (n = 7), and of those, barriers to linkage-to-cure include (1) the high cost of getting treated, (2) language barriers, (3) transportation to get to a medical provider, (4) lack of information, and (5) limited ability to navigate the healthcare system. Cost barriers were most commonly cited, especially among the Spanish-speaking participants. Participants mentioned the high cost of insurance and personal or family financial instability that prevented them from initiating or continuing HCV treatment. Language barriers were also substantial concerns. “Since I don’t speak 100% English, I was treated at the hospital in Los Angeles and one doctor was a liver doctor, the other one was a hepatitis doctor, the other one was a cirrhosis doctor, and I didn’t understand very well what they were telling me. And the medications were in English, and so I withdrew a little bit and I didn’t want to take care of myself anymore because I didn’t understand anything. Now I just changed… to another primary care doctor who explains it well in Spanish and in 20 minutes, he explained the hepatitis C.” (Untreated Spanish-speaking Study Participant #1) Lack of information emerged as a significant theme across interviews, indicating that insufficient or unclear information about Hepatitis C and treatment options is a common experience. This theme reflects a patient-level gap in understanding Hepatitis C, its implications, and available treatments. The prevalence of this theme highlights a critical gap in community-level and patient education and the absence of health communication that may be contributing to treatment avoidance or delay. This knowledge gap emerged as a significant barrier to treatment engagement among the interviewed participants. “ I hadn’t heard so much about [HCV at the time of my diagnosis]… I don’t really know all that stuff about Hepatitis, what causes it or what is up with that. ” (Untreated Spanish-Speaking Study Participant #2) “ Okay, all right, ‘cause I feel like a real dummy right now… I didn’t get this information [previously, but] even [the] little bit you’ve given me [during the interview], it makes sense. ” (Untreated English-speaking Study Participant #5) Frustration with navigating the healthcare system emerged as another prominent theme, particularly among Spanish-speaking participants. This theme reflects feelings of dissatisfaction or annoyance regarding healthcare experiences. It also captures broader discontent with the quality of care provided. “ I tried [to get treatment] before, but at least 3 or 4 times, and [they] all have been unsuccessful because of the blood draw process… I was an IV drug user, so I have collapsed veins… For test, [they need] sometimes two tests, not just one. I remember at one clinic, they were successful, albeit after a few tries, you know, of poking me with a needle. But the second [visit] was unsuccessful. And they needed that second blood test in order to prescribe medicine to treat it. And that second blood draw wasn’t successful. ” (Untreated English-speaking Study Participant #3) Preliminary observations among Spanish-speaking untreated participants suggest a potential trend toward frustration with their healthcare experiences, warranting further research regarding potential language-related or cultural barriers in provider-patient relationships. This frustration may further discourage engagement with the healthcare system for Hepatitis C treatment. Participants described experiences where they felt dismissed, not taken seriously, or treated impersonally by healthcare providers. These negative interactions appeared to create lasting impressions that discouraged future treatment-seeking behavior. Facilitators of accessing Hepatitis C treatment among untreated English and Spanish-speaking study partic
## Related Clinical Research

- [HPV prevalence and genotype distribution in women from northern Lao PDR (2018–2019)](https://medichelpline.com/clinical-feed/plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from.md)
- [NOX2 drives HBV replication via ROS-induced autophagy in cell models](https://medichelpline.com/clinical-feed/pubmed-43059380.md) (DOI: 10.3892/ijmm.2026.6054)
- [Infections in Adult Liver Transplant Hospitalizations Linked to Higher Mortality and Costs](https://medichelpline.com/clinical-feed/plos-one-2-burden-and-impact-of-infections-among-adult-liver-transplantation-related.md)
- [Continuous luminescence monitoring of hepatitis C virus and orthoflavivirus infections](https://medichelpline.com/clinical-feed/pubmed-42861980.md) (DOI: 10.1128/jvi.01266-26)
- [Sentinel Surveillance Identifies Threats to SMC Effectiveness in Northern Kenya](https://medichelpline.com/clinical-feed/medrxiv-2-sentinel-event-surveillance-to-identify-threats-to-smc-effectiveness.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.